Table 3 Multivariable Cox analysis for advanced prostate patients with prior cancer (vs. no prior cancer)

All patients

1.13 (1.02–1.26)

0.017

0.93 (0.81–1.06)

0.248

Part I: Prior cancer timing

(vs. no prior cancer)

≤ 1 year

1.35 (1.11–1.66)

0.003

0.80 (0.60–1.08)

0.152

1–2 year

1.27 (1.02–1.57)

0.033

0.97 (0.72–1.29)

0.818

2–3 year

1.18 (0.93–1.49)

0.176

0.78 (0.56–1.09)

0.150

3–5 year

1.14 (0.94–1.37)

0.180

0.97 (0.77–1.23)

0.792

5–10 year

1.05 (0.89–1.24)

0.535

0.93 (0.76–1.15)

0.512

>10 year

1.11 (0.92–1.33)

0.270

1.09 (0.88–1.35)

0.432

Part II: Prior cancer stage

(vs. no prior cancer)

In situ

1.13 (0.87–1.47)

0.365

0.90 (0.64–1.27)

0.539

Localized

1.05 (0.91–1.21)

0.537

0.87 (0.73–1.05)

0.139

Regional

1.27 (0.97–1.68)

0.083

0.91 (0.70–1.19)

0.488

Distant

1.31 (1.08–1.58)

0.007

0.77 (0.51–1.16)

0.206

Part III: Prior cancer type

(vs. no prior cancer)

Urinary bladder

1.39 (1.16–1.66)

< 0.001

0.98 (0.77–1.26)

0.880

Colon and cecum

1.23 (1.02–1.48)

0.034

0.67 (0.67–1.11)

0.243

Melanoma of the skin

1.02 (0.70–1.19)

0.502

0.93 (0.68–1.26)

0.618

Non-hodgkin lymphoma

1.16 (0.89–1.52)

0.277

1.22 (0.89–1.65)

0.213

Rectum

1.10 (0.81–1.48)

0.546

0.78 (0.52–1.19)

0.250

Lung and bronchus

1.54 (1.15–2.08)

0.004

0.90 (0.58–1.42)

0.658

Kidney and renal pelvis

0.79 (0.57–1.09)

0.154

0.70 (0.47–1.06)

0.096

Chronic lymphocytic leukemia

1.47 (1.01–2.15)

0.046

1.10 (0.66–1.85)

0.707

larynx

1.06 (0.64–1.76)

0.819

0.94 (0.50–1.78)

0.850

Others

1.05 (0.89–1.24)

0.576

0.92 (0.77–1.14)

0.447